At 16.2x earnings and 14.3x forward earnings, the stock is priced as a stable, mid-tier insurer rather than a high-growth compounder, yet the 2.3 forward PEG signals investors are already paying a premium relative to its growth outlook. The absence of an Altman Z-Score and Debt/Equity data limits balance sheet transparency, which is not trivial in Financial Services. EPS of 13.3 against an estimated 6.84 next year suggests a sharp earnings compression, which makes the multiple less attractive than it appears at first glance. This is not an obvious mispricing; it looks like a fairly valued insurer with muted growth and questionable forward momentum.